Search for other papers by Giulia Bresciani in
Google Scholar
PubMed
Search for other papers by Angeliki Ditsiou in
Google Scholar
PubMed
Search for other papers by Chiara Cilibrasi in
Google Scholar
PubMed
Search for other papers by Viviana Vella in
Google Scholar
PubMed
Search for other papers by Federico Rea in
Google Scholar
PubMed
Search for other papers by Marco Schiavon in
Google Scholar
PubMed
Search for other papers by Narciso Giorgio Cavallesco in
Google Scholar
PubMed
Search for other papers by Georgios Giamas in
Google Scholar
PubMed
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
Search for other papers by Teresa Gagliano in
Google Scholar
PubMed
linsitinib were purchased from Selleckchem. Compounds were dissolved in DMSO and stored at −80°C as 10 mM stock solutions. EGF and IGF1 were purchased from ProSpec protein specialists (East Brunswick, NJ, USA); VEGF was purchased from Peprotech Inc (Rocky
Department of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Shinagawa, Tokyo, Japan
Search for other papers by Yusaku Mori in
Google Scholar
PubMed
Search for other papers by Eunhyoung Ko in
Google Scholar
PubMed
Search for other papers by Rudolf Furrer in
Google Scholar
PubMed
Search for other papers by Linda C Qu in
Google Scholar
PubMed
Search for other papers by Stuart C Wiber in
Google Scholar
PubMed
Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada
Division of Endocrinology and Metabolism, Leadership Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada
Search for other papers by I George Fantus in
Google Scholar
PubMed
Search for other papers by Mario Thevis in
Google Scholar
PubMed
Department of Pathology, Humber River Regional Hospital, Toronto, Ontario, Canada
Search for other papers by Alan Medline in
Google Scholar
PubMed
Search for other papers by Adria Giacca in
Google Scholar
PubMed
Belfiore A. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling . Clinical Cancer Research 1999 5 1935
Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Ken K Y Ho in
Google Scholar
PubMed
Search for other papers by Bradley S Miller in
Google Scholar
PubMed
Search for other papers by Ignacio Bergada in
Google Scholar
PubMed
Search for other papers by Alan D Rogol in
Google Scholar
PubMed
deficiencies ≥3 and low IGF-I Tumors of the skull base and/or their treatment Congenital Pituitary adenoma Genetic Craniopharyngioma Transcription factor defects (PIT-1, PROP-1, LHX3/4, HESX-1, PITX-2) Rathke’s cleft cyst
Search for other papers by Cecilia Follin in
Google Scholar
PubMed
Search for other papers by Sven Karlsson in
Google Scholar
PubMed
diabetes and hypertension ( 3 , 4 ). The aims of treatment for acromegaly are to control/reduce tumour size, normalise GH and insulin-like growth factor 1 (IGF-1) levels and to improve comorbidities. Current treatments consist of surgery, medical therapy
Department of Anatomy and UMIB (Unit for Multidisciplinary Biomedical Research) of ICBAS, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Department of Endocrinology, University of Porto, Porto, 4050-313, Portugal
Search for other papers by Sofia S Pereira in
Google Scholar
PubMed
Search for other papers by Tiago Morais in
Google Scholar
PubMed
Search for other papers by Madalena M Costa in
Google Scholar
PubMed
Search for other papers by Mariana P Monteiro in
Google Scholar
PubMed
Department of Anatomy and UMIB (Unit for Multidisciplinary Biomedical Research) of ICBAS, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Department of Endocrinology, University of Porto, Porto, 4050-313, Portugal
Search for other papers by Duarte Pignatelli in
Google Scholar
PubMed
proliferation (Ki-67), and cell adhesion (E-cadherin and β-catenin), and the growth factor IGF2 and its receptor IGF1R. Subjects and methods Patients and tumors Paraffin-embedded adrenal samples from a total of 43 patients were used. These included ACA samples
Search for other papers by Annalisa Blasetti in
Google Scholar
PubMed
Search for other papers by Valeria Castorani in
Google Scholar
PubMed
Search for other papers by Nella Polidori in
Google Scholar
PubMed
Search for other papers by Ilaria Mascioli in
Google Scholar
PubMed
Search for other papers by Francesco Chiarelli in
Google Scholar
PubMed
Search for other papers by Cosimo Giannini in
Google Scholar
PubMed
, particularly intensified insulin regimens and novel technologies, can improve metabolic control in patients with T1D, therefore preventing abnormalities of the GH–IGF-I axis, thus potentially leading to normal growth and final height similar to unaffected peers
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Xiaohui Qi in
Google Scholar
PubMed
Search for other papers by Ping He in
Google Scholar
PubMed
Search for other papers by Huayan Yao in
Google Scholar
PubMed
Search for other papers by Huanhuan Sun in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Jiying Qi in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Min Cao in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Bin Cui in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Guang Ning in
Google Scholar
PubMed
Pezzino V Squatrito S Belfiore A Vigneri R . The role of insulin receptors and IGF-I receptors in cancer and other diseases . Archives of Physiology and Biochemistry 2008 114 23 – 37 . ( https://doi.org/10.1080/13813450801969715 ) 10 Calle EE
Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Search for other papers by Peter Wolf in
Google Scholar
PubMed
Search for other papers by Alexandre Dormoy in
Google Scholar
PubMed
Search for other papers by Luigi Maione in
Google Scholar
PubMed
Search for other papers by Sylvie Salenave in
Google Scholar
PubMed
Search for other papers by Jacques Young in
Google Scholar
PubMed
Search for other papers by Peter Kamenický in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
). Among the 25 patients resistant to first-generation SRLs, 16 (64%) normalized their IGF-I levels under pasireotide. Figure 1 (A) Longitudinal changes in IGF-1 (given as % of ULN) in all patients; patients who had normalized IGF-1 levels according
Search for other papers by Ursula M M Costa in
Google Scholar
PubMed
Search for other papers by Carla R P Oliveira in
Google Scholar
PubMed
Search for other papers by Roberto Salvatori in
Google Scholar
PubMed
Search for other papers by José A S Barreto-Filho in
Google Scholar
PubMed
Search for other papers by Viviane C Campos in
Google Scholar
PubMed
Search for other papers by Francielle T Oliveira in
Google Scholar
PubMed
Search for other papers by Ivina E S Rocha in
Google Scholar
PubMed
Search for other papers by Joselina L M Oliveira in
Google Scholar
PubMed
Search for other papers by Wersley A Silva in
Google Scholar
PubMed
Search for other papers by Manuel H Aguiar-Oliveira in
Google Scholar
PubMed
-0545 . 5 Colao A 2008 The GH–IGF-I axis and the cardiovascular system: clinical implications . Clinical Endocrinology 69 347 – 358 . doi:10.1111/j.1365-2265.2008.03292.x . 6 Gazzaruso C Gola M Karamouzis I Giubbini R Giustina A 2014
Search for other papers by Jin Kyu Oh in
Google Scholar
PubMed
Search for other papers by Young Jae Im in
Google Scholar
PubMed
Search for other papers by Kwanjin Park in
Google Scholar
PubMed
Search for other papers by Jae-Seung Paick in
Google Scholar
PubMed
underlying molecular mechanisms have not been described, the GH–insulin-like growth factor 1 (IGF1) axis is a proactive mediator of the actions of testosterone and its potent derivative dihydrotestosterone. Accordingly, stimulation of IGF1 signalling